3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Phase 2
1
Status
Recruiting
8
Completed
4
Active not recruiting
4
Terminated
3
Not yet recruiting
3
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
1
Interventions
pembrolizumab
61
Radiotherapy
55
Gemcitabine
51
Paclitaxel
49
Cyclophosphamide
48
Cisplatin
48
Carboplatin
45
Dexamethasone
37
Bevacizumab
37
Nivolumab
35
Fluorouracil
34
Docetaxel
34
Oxaliplatin
33
durvalumab
32
Rituximab
28
Magnetic Resonance Spectroscopy
28
Leucovorin
28
Drug Therapy
25
Pemetrexed
24
Doxorubicin
24
Capecitabine
24
atezolizumab
22
Radiation
20
Cytarabine
20
Radiosurgery
19
Prednisone
19
Etoposide
19
Irinotecan
17
Bortezomib
17
Cetuximab
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Withdrawn
×
tafasitamab
×
Clear all
NCT07030699
2026-04-07
ECLAT
Memorial Sloan Kettering Cancer Center
Phase 2
Withdrawn